Table 2

Association between XRCCI Arg399Gln polymorphism and breast cancer risk

Cases (N = 1088)Controls (N = 1182)ORa (95% CI)ORb (95% CI)
Allele frequency
 G(Arg)1564 (71.9)1718 (72.7)
 A(Glu)612 (28.1)646 (27.3)P = 0.55
Genotype
 Arg/Arg561 (51.6)610 (51.6)1.00 (ref)c1.00 (ref)
 Arg/Glu442 (40.6)498 (42.1)0.92 (0.77–1.09)0.90 (0.76–1.08)
 Glu/Glu85 (7.8)74 (6.3)1.22 (0.87–1.71)1.20 (0.85–1.69)
Premenopausal women
 Arg/Arg373 (51.2)368 (48.5)1.00 (ref)1.00 (ref)
 Arg/Glu295 (40.5)340 (44.9)0.79 (0.63–0.98)0.79 (0.63–0.98)
 Glu/Glu61 (8.4)50 (6.6)1.20 (0.79–1.81)1.19 (0.78–1.80)
Postmenopausal women
 Arg/Arg188 (52.4)242 (57.1)1.00 (ref)1.00 (ref)
 Arg/Gln147 (40.9)158 (37.3)1.21 (0.90–1.64)1.19 (0.87–1.62)
 Gln/Gln24 (6.7)24 (5.7)1.19 (0.65–2.17)1.13 (0.61–2.11)
Age < 45 yrs
 Arg/Arg213 (48.9)251 (51.2)1.00 (ref)1.00 (ref)
 Arg/Gln185 (42.4)207 (42.2)0.95 (0.72–1.26)0.94 (0.70–1.24)
 Gln/Gln38 (8.7)32 (6.5)1.39 (0.83–2.34)1.39 (0.82–2.36)
Age ≥ 45 yrs
 Arg/Arg348 (53.4)359 (51.9)1.00 (ref)1.00 (ref)
 Arg/Gln257 (39.4)291 (42.1)0.90 (0.72–1.13)0.89 (0.71–1.12)
 Gln/Gln47 (7.2)42 (6.1)1.11 (0.71–1.73)1.07 (0.68–1.67)
  • a OR, odds ratio; CI, confidence interval. Adjusted for age.

  • b Additional adjustment for education, family history of breast cancer, menopausal status, age at menarche, age at menopause, body mass index, waist:hip ratio, and physical activity.

  • c Ref, reference.